| Dr Richard R Graham, MD | |
|
5339 Odonavan, Baton Rouge, LA 70808-4388 | |
| (225) 766-4999 | |
| (225) 763-5870 |
| Full Name | Dr Richard R Graham |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 5339 Odonavan, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356302681 | NPI | - | NPPES |
| 1678309 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | MD010249 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard R Graham, MD 5339 Odonavan, Baton Rouge, LA 70808-4388 Ph: (225) 766-4999 | Dr Richard R Graham, MD 5339 Odonavan, Baton Rouge, LA 70808-4388 Ph: (225) 766-4999 |
News Archive
Sigma-Aldrich Corporation, a leading Life Science and Technology Company, today announced it has signed an agreement with Public Health England to manufacture and supply bacterial and fungal NCTC/NCPF Certified Reference Materials (CRM) in LENTICULE disc format worldwide for use as controls in food, water, environmental and clinical testing microbiology laboratories.
The use of common and readily available screening tests - like the ankle brachial index (ABI) - along with traditional risk scoring systems - such as the Framingham Risk Score - has the potential to prevent devastating heart attacks in thousands of individuals who are not originally thought to be at high risk (according to Framingham alone), say researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting.
As a noninvasive method of determining the sex of a fetus, tests using cell-free fetal DNA obtained from the mother's blood after 7 weeks gestation performed well, while urine-based tests appear to be unreliable, according to a review and analysis of previous studies, reported in the August 10 issue of JAMA.
AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).
› Verified 6 days ago
Dr. Brian W. Webb, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 5339 Odonavan, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-767-4702 | |
Zarius Drummond, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5339 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-767-4702 | |
Dr. Leo A. Pei, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 17000 Medical Center Drive, Baton Rouge, LA 70816 Phone: 225-752-2470 | |
Jennifer Jastram-belcher, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5339 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-767-4702 | |
Dr. Peggy H. Polk, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 5339 Odonavan, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-763-5870 | |
Jonathan C Stone, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5339 O'donovan Drive, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-767-4702 | |
Amberly Lindau Nunez, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 5339 Odonovan Dr, Baton Rouge, LA 70808 Phone: 225-766-4999 Fax: 225-767-4702 |